Supplementary data from: Bisphosphonates maintain BMD after sequential teriparatide and denosumab in Premenopausal Women with Idiopathic Osteoporosis (PremenIOP)

Context: We previously reported that sequential teriparatide followed by denosumab substantially increases BMD in premenopausal idiopathic osteoporosis (PremenIOP).
Objective: To determine whether bisphosphonates prevent bone loss after denosumab cessation in PremenIOP
Design: Open-label extension study
Participants: 24 PremenIOP Teriparatide-Denosumab Study participants
Interventions: Oral alendronate (ALN), 70 mg weekly, or IV zoledronic acid (ZOL), 5mg once (patient choice), was administered 7 months (M) after final denosumab dose.
Outcomes: BMD by DXA and serum C-telopeptide (CTX) q6M; vertebral fracture assessment (VFA) and HR-pQCT q12M.
Results: 24 women with PremenIOP (aged 43±8 years), severely affected with low trauma adult fractures (range 0-12; 9 with vertebral fractures) and/or very low BMD, had large BMD increases on sequential teriparatide-denosumab (spine: 25±9%; total hip: 11±6%). During the Bisphosphonate Extension, mean BMD and CTX changes in the entire group were smal..., , , # Supplementary data from: Bisphosphonates maintain BMD after sequential teriparatide and denosumab in Premenopausal Women with Idiopathic Osteoporosis (PremenIOP)

## Description of the data and file structure

Supplementary Table: Supplementary_Table_BisextR1.csv

Changes in spine and hip BMD and CTX in (1) those who received 36M of denosumab vs those who received less than 36M of denosumab and (2) those who remained premenopausal vs those who transitioned to menopause before/during the study.

Abbreviations: LS – lumbar spine; TH – total hip; FN – femoral neck; CTX – C-telopeptide; M - months
,